Takeaway
- Combination bendamustine, carboplatin, and dexamethasone (BCD) delivered high, durable rates of complete remission in patients with relapsed/refractory peripheral T-cell lymphomas (R/R PTCL).
Why this matters
- High-dose chemotherapy and autologous stem cell transplant (ASCT) is an acceptable salvage strategy in eligible patients with PTCL; however, prognosis is poor in the 60%-70% of patients who are ineligible for ASCT resulting from disease progression.
Study design
- Phase 2 BENCART study of BCD in 28 patients with R/R PTCL.
- Patients in complete or partial remission (CR/PR) with 2 courses of BCD were eligible for ASCT; the remaining patients could proceed to ASCT after 4 cycles of BCD, or continue to 6 BCD cycles.
- Funding: None disclosed.
Key results
- Objective response after 2 cycles of BCD (R2):
- 54%: 19% CR; 35% PR.
- Median duration of response after R2: 5.3 (range, 0.4-21.9) months.
- Objective response after completion of planned treatment (Rmax):
- 54%: 29% CR; 25% PR.
- Median PFS:
- 4.4 (95% CI, 2.8-6.0) months overall.
- 20.2 (range, 6.3-20.5) months with BCD followed by ASCT.
- 12.4 months in patients with angioimmunoblastic T-cell lymphoma (AITL).
- Grade 3-4 toxicities (expressed as percentage of 85 cycles) included thrombocytopenia (39%) and neutropenia (18%).
Limitations
- Single-group design.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionalsLogin to
account
Don’t have an account? Get started